Specialty pharma co deploys Semantelli's AETracker TM
Semantelli Corporation said that a global, multibillion specialty pharmaceutical company has deployed Semantelli’s AETracker TM to detect and manage the adverse events and product complaints generated in the company sponsored mobile applications.
Siva Nadarajah, CEO of Semantelli Corp said, “We are really excited about this development in the mhealth sector. By deploying Semantelli, companies are starting to ensure sponsored mobile applications are compliant from pharmacovigilance perspective.”
Mr. Siva also said, “There are thousands of mobile health applications available on smart phones and tablets. The majority of them are not even in the sponsor’s pharmacovigilance radar . We feel all of these applications require monitoring on an ongoing basis.”
There are about 13,000 health applications for consumers on iTunes and Google Play and only 100 of them are approved by FDA, states the news reports.
According to Microsoft Founder Bill Gates, the mobile devices are expected to provide health care to more than 500 million people by 2015. It will also improve immunization programmes and also offer cheap diagnostic tools to fight many of the world’s diseases.
In August 2011, Semantelli introduced AETracker to assist the pharmaceutical companies monitor and manage the adverse events reported on company owned Facebook pages.
AETracker helps the pharmaceutical companies monitor and respond to potential adverse events, product complaints, and off-label comments on company sponsored social media and mobile applications.
Semantelli is a leader in Semantic based enterprise listening solutions for global life sciences industry. The companies use Semantelli’s compliance sensitive solutions to monitor social media, web, and internal unstructured data sources to find previously unknown early warnings, threats and opportunities.
Skin Analytics wins NHSX award for AI skin cancer tool
An artificial intelligence-driven tool that identifies skin cancers has received an award from NHSX, the NHS England and Department of Health and Social Care's initiative to bring technology into the UK's national health system.
NHSX has granted the Artificial Intelligence in Health and Care Award to DERM, an AI solution that can identify 11 types of skin lesion.
Developed by Skin Analytics, DERM analyses images of skin lesions using algorithms. Within primary care, Skin Analytics will be used as an additional tool to help doctors with their decision making.
In secondary care, it enables AI telehealth hubs to support dermatologists with triage, directing patients to the right next step. This will help speed up diagnosis, and patients with benign skin lesions can be identified earlier, redirecting them away from dermatology departments that are at full capacity due to the COVID-19 backlog.
Cancer Research has called the impact of the pandemic on cancer services "devastating", with a 42% drop in the number of people starting cancer treatment after screening.
DERM is already in use at University Hospitals Birmingham and Mid and South Essex Health & Care Partnership, where it has led to a significant reduction in unnecessary referrals to hospital.
Now NHSX have granted it the Phase 4 AI in Health and Care Award, making DERM available to clinicians across the country. Overall this award makes £140 million available over four years to accelerate the use of artificial intelligence technologies which meet the aims of the NHS Long Term Plan.
Dr Lucy Thomas, Consultant Dermatologist at Chelsea & Westminster Hospital, said: “Skin Analytics’ receipt of this award is great news for the NHS and dermatology departments. It will allow us to gather real-world data to demonstrate the benefits of AI on patient pathways and workforce challenges.
"Like many services, dermatology has severe backlogs due to the COVID-19 pandemic. This award couldn't have come at a better time to aid recovery and give us more time with the patients most in need of our help.”